Komori
M

Meiji Holdings Co.,Ltd.

2269FoodLarge cap
4,349JPY+4.6%
★ Watch (sign-up required)
Price history
¥4,349Latest+30.6%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

The Group is headed by a pure holding company and has 67 subsidiaries and 7 affiliates. Its two primary segments are Food and Pharmaceuticals. Key products include yogurt, milk products, beverages, cheese, butter, margarine, cream, ice cream, prepared foods, chocolate, gummies, sports nutrition products and infant formula in the Food segment, and prescription drugs and animal health products in the Pharmaceuticals segment. Through its domestic and overseas operations, the Group aims to provide health- and nutrition-focused products in global markets. The fiscal 2026 medium-term plan sets targets including integrated ROESG, higher consolidated operating profit, overseas sales, ROIC and ROE, maintaining and improving the total payout ratio, and achieving the integrated ROESG score target.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Key numbersShowing 8 of 20
PER
78.67How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.
PBR
1.47How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
1.9%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥1.2tnShare price × number of shares. The value of the entire company.
Equity ratio
60.1%The proportion of assets funded by money that does not have to be repaid.
Operating margin
7.8%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
3.3%The average annual growth in sales over the past three years.
What to watch next
Progress of the Japan Fair Trade Commission's investigation into suspected coordination of ice cream selling prices, including whether sanctions or corrective measures are imposed and whether additional disclosure is made
Unknown, depending on the progress of the response to the authoritiesImpact HighLikelihood Medium
Disclosure of how much shipments and supply performance for KOSTAIVE intramuscular injection, a next-generation mRNA vaccine supplied in two-person vials, contributed to the increase in routine vaccinations
Results disclosed with the next earnings release or interim resultsImpact MediumLikelihood Medium
Clinical and development milestones for pharmaceutical investment themes, including KD-414, such as Phase 3 progress and updates on co-development
Unknown, depending on the clinical scheduleImpact MediumLikelihood Low
Confirmation of progress against the medium-term plan, including Integrated ROESG, consolidated operating profit, overseas sales, ROIC/ROE and the total payout ratio, together with evidence supporting margin improvement
Updates through fiscal 2026 plan management and the earnings periodImpact MediumLikelihood Medium
What to watch next
Loading
Who owns itTop holders total 35.7%
Listed holders 35.7%Everyone else 64.3%
The Master Trust Bank of Japan (Trust Account)15.40%
Custody Bank of Japan, Ltd. (Trust Account).5.43%
Nippon Life Insurance Company (standing proxy: The Master Trust Bank of Japan, Ltd.)2.40%
The Norinchukin Bank2.07%
明治ホールディングス従業員持株会1.99%
STATE STREET BANK WEST CLIENT - TREATY 5052341.98%
明治ホールディングス取引先持株会1.90%
㈱みずほ銀行(常任代理人 日本カストディ銀行)1.73%
2 other listed holders2.77%
Who owns it
HolderOwnership (%)
The Master Trust Bank of Japan (Trust Account)15.40
Custody Bank of Japan, Ltd. (Trust Account).5.43
Nippon Life Insurance Company (standing proxy: The Master Trust Bank of Japan, Ltd.)2.40
The Norinchukin Bank2.07
明治ホールディングス従業員持株会1.99
STATE STREET BANK WEST CLIENT - TREATY 5052341.98
明治ホールディングス取引先持株会1.90
㈱みずほ銀行(常任代理人 日本カストディ銀行)1.73
2 other listed holders2.77
This company's documents
Timely disclosures
Threads